Volver a Agenda
Engaging the Rare Disease Community to Design Clinical Trials
Session Chair(s)
Scott Schliebner, MPH
Senior Vice President, Clinical Development Services, TFS Health Science, United States
In this session, participants will hear several recent examples of how to best engage with different patient communities with respect to clinical trial design.
Learning Objective : Discuss examples of how to best engage with different patient communities with respect to clinical trial design.
Speaker(s)
Scott Schliebner, MPH
Senior Vice President, Clinical Development Services, TFS Health Science, United States
Nothing About Us, Without Us: Best Practices for Engaging With the Rare Disease Patient Community
Bruce Wynne, PHARMD
Senior Director , Clinical Operations, Taiho Oncology, Inc., United States
Enrollment: Using Patient Advocacy Groups to Design a Better Trial and Manage Studies in Rare Diseases
Deborah Hartman, PHD
Vice President, Global Program Leader, Takeda Pharmaceuticals International, Inc., United States
Early Engagement with the Kabuki Syndrome Patient Community to Understand Clinical Phenotype and Unmet Needs
¿Tiene una cuenta?